IL-5 in the plasma-cell-dominant Castleman disease: a nosological entity

Pahadiya, Hans Raj; Choudhary, Ankita; Gandhi, Ronak; Prajapati, Gopal Raj; Lakhotia, Manoj

doi:10.1093/omcr/omw041

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-5 is a Th2 cytokine that induces eosinophilia and also promotes immunoglobulin secretion by B cells [21]. IL-5 levels have been reported to increase following KSHV infection and in KSHV-associated conditions [28,29]. We observed higher IL-5 levels at baseline and follow up among the responders compared to the poor responders.…”

Section: Plos Onementioning

confidence: 52%

Outcome markers of ART-treated HIV+ patients with early stage Kaposi’s sarcoma

et al. 2020

View full text Add to dashboard Cite

HIV-associated/epidemic Kaposi's sarcoma (EpKS) is an AIDS-defining angio-proliferative malignancy. It can be treated with antiretroviral therapy (ART) alone or with ART plus cytotoxic chemotherapy. ART-treated EpKS can either respond or worsen upon treatment. This study aimed at identifying immunological markers of ART-treatment response. We compared responders (those with clinical EpKS tumor regression) versus poor responders (those with progressive or non-responsive EpKS). We measured plasma cytokine and chemokine levels using cytometric bead assays. Kaposi's sarcoma herpesvirus (KSHV) neutralizing antibody (nAb) responses were also quantified to test associations with treatment outcome. Interleukin (IL)-5 levels were significantly elevated in responders versus poorresponders at baseline (0.76pg/ml vs. 0.37pg/ml; p<0.01) and follow-up (0.56pg/ml vs. 0.37pg/ml; p<0.01); IL-6 was lower in responders than poor-responders at follow-up (600fg/ ml vs. 4272fg/ml; p<0.05). IP-10/CxCL-10 was significantly lower at follow-up in responders versus poor-responders (187pg/ml vs. 528pg/ml; p<0.01). KSHV nAb were not significantly differential between responders and poor-responders. In conclusion, high plasma IL-5 at baseline could be a marker for ART-treated KS tumor regression, whereas increased proinflammatory cytokine IL-6, and the chemokine IP-10, associate with KS tumor progression.

show abstract

Section: Plos Onementioning

confidence: 52%

Outcome markers of ART-treated HIV+ patients with early stage Kaposi’s sarcoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although our qPCR analyses implicate pathogenic roles of the IL-6-CCL17/CCL26 axis in the development of this unique EGE, the molecular mechanisms accounting for the accumulation of eosinophils have not been clarified. Infiltration of eosinophils is reported in patients with Castleman disease and is driven by IL-6 (28,29). However, the accumulation of eosinophils in Castleman disease is accompanied by the increased production of IL-5, suggesting that the accumulation of eosinophils associated with IL-6 production requires enhanced IL-5 produc-tion (28,29).…”

Section: Discussionmentioning

confidence: 99%

“…Infiltration of eosinophils is reported in patients with Castleman disease and is driven by IL-6 (28,29). However, the accumulation of eosinophils in Castleman disease is accompanied by the increased production of IL-5, suggesting that the accumulation of eosinophils associated with IL-6 production requires enhanced IL-5 produc-tion (28,29). In contrast, PSL treatment increased and decreased the mRNA expression of IL-5 and IL-6 in the duodenal mucosa, respectively.…”

Section: Discussionmentioning

confidence: 99%

Circumferential Stenosis of the Second Part of the Duodenum Caused by Eosinophilic Gastroenteritis

Honjo,

Minaga,

Hara

et al. 2024

Intern. Med.

View full text Add to dashboard Cite

Isolated eosinophilic gastroenteritis (EGE) of the second part of the duodenum is rare. We herein report a case of EGE limited to the second part of the duodenum that caused circumferential stenosis due to massive wall thickening. A boring biopsy was useful to verify the accumulation of eosinophils. Induction of remission by prednisolone was accompanied by a marked reduction in the mRNA expression of IL-6, C-C motif chemokine ligand 17 (CCL17), and CCL26 without any reduction in prototypical EGE-associated T helper type 2 cytokines (IL-5, IL-13). Thus, the enhanced expression of IL-6, CCL17, and CCL26 might be involved in the development of EGE in this case.

show abstract

“…However, only part of the phenomenon can be explained with the mechanism. Some scholars have also explored other mechanisms besides HHV-8 and IL-6, such as TNF, MCSF, IL-1 [ 11 ], IL-5 [ 12 ], CMV [ 13 ], and EBV [ 14 , 15 ], and proposed that they might be related to the occurrence of CD. However, there is a lack of studies with large samples.…”

Section: Discussionmentioning

confidence: 99%

Clinical Analysis of Castleman’s Disease of the Lacrimal Gland

Tang

Sun

2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Objective. To explore the clinical manifestations, imaging characteristics, and pathological characteristics of Castleman’s disease of the lacrimal gland, enhance the knowledge of the disease, and improve the level of its diagnosis and treatment. Methods. In the retrospective study, the data of 5 patients diagnosed with Castleman’s disease of the lacrimal gland in Tianjin Medical University Eye Hospital from 2014 to 2018 were analyzed, and the relevant literature was reviewed. Results. All the 5 patients were confirmed by pathological examination. Clinical manifestations were characterized by mass occupying lesions in the lacrimal gland area, without obvious pain, accompanied by eyelid swelling and ptosis, as well as space-occupying symptoms. Imaging examination showed that there was a soft tissue mass in the enlarged lacrimal gland area, and the mass was rich in blood flows while showing no obvious specificity, which could invade the surrounding muscles. All patients underwent surgical resection. Pathological results showed that 1 case was of the hyaline-vascular type, 3 cases were of the plasma cell type, and 1 case showed malignant transformation to plasma cell tumor. Conclusion. Castleman’s disease of the lacrimal gland is a rare orbital lymphoproliferative disease lacking specificity in clinical manifestations and imaging examination. As there are difficulties in differentiating the disease from orbital inflammatory pseudotumor and orbital lymphoma, its diagnosis still depends on pathological examination. The disease is mainly treated with surgical resection, and the pathological type is determined postoperatively.

show abstract

IL-5 in the plasma-cell-dominant Castleman disease: a nosological entity

Cited by 5 publications

References 9 publications

Outcome markers of ART-treated HIV+ patients with early stage Kaposi’s sarcoma

Outcome markers of ART-treated HIV+ patients with early stage Kaposi’s sarcoma

Circumferential Stenosis of the Second Part of the Duodenum Caused by Eosinophilic Gastroenteritis

Clinical Analysis of Castleman’s Disease of the Lacrimal Gland

Contact Info

Product

Resources

About